MYB and acute myeloid leukemia: Overexpression of oncogenes (FLT3, MYB, DNMT3B, and MYCN) in DX vs CR1 samples reinforces their usefulness in minimal residual disease monitoring, especially in AML-NK with no genetic aberrations.